All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Join our
How to sequence BCMA-directed therapies in early relapsed/ refractory multiple myeloma
At the ESH 7th Translational Research Conference:
Multiple Myeloma
with Martin Kaiser, Mohamad Mohty, and Rakesh Popat
Saturday, October 5, 2024 | 09:10-10:10 CEST
Register nowThis independent educational activity is funded by GSK. All content is developed independently by the faculty. The funders are allowed no influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved isatuximab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.1
This approval was based on data from the phase III IMROZ (NCT03319667) trial.
IMROZ, an open-label, phase III trial, enrolled adult patients with newly diagnosed multiple myeloma ineligible for transplant. Patients were randomly assigned 3:2 to receive isatuximab-VRd (Isa-VRd) or VRd alone. The primary endpoint was progression-free survival (PFS), with secondary endpoints including complete response, measurable residual disease negativity, and overall survival (OS).
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox